Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | ImmunoSarc2: doxorubicin and dacarbazine with nivolumab in leiomyosarcoma

Javier Martin Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, discusses findings from the Phase Ib ImmunoSarc2 (NCT03277924) of doxorubicin and dacarbazine plus nivolumab in patients with leiomyosarcoma. The trial consists of eight cohorts, where cohorts 1-6 received sunitinib plus nivolumab, and results from cohort 7 were presented in this talk. The therapeutic regimen was found to be tolerable in patients, where preliminary efficacy was additionally reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.